



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	J-Lat Full Length Cells (10.6)
Catalog Number:	9849
Lot Number:	160129
Release Category:	C
Provided:	1 mL of cells at 7.7×10^6 cells/mL. Viability is 78%.
Cell Type:	Jurkat - T lymphocyte cell line
Propagation Medium:	RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/mL), streptomycin (100 µg/mL), L-glutamine (2 mM, 0.3 mg/mL).
Freeze Medium:	FBS, 90%; DMSO, 10%.
Growth Characteristics:	No special requirements, split 1:3 at 1×10^6 cells/mL.
Morphology:	Small, spherical cells that grow in suspension usually singly but some clumping has been noted.
Sterility:	Negative for bacteria, mycoplasma, and fungi
Description:	This is a Jurkat-based cell line containing a full-length integrated HIV-1 genome that expresses GFP upon activation. The genome generates incomplete virions due to a frameshift in env.
Special Characteristics:	<p>Jurkat cells were infected with the packaged retroviral construct HIV-R7/E-/GFP, which is full length HIV-1 genome with a non-functional Env due to a frameshift, and GFP in place of the Nef gene.</p> <p>Full-length constructs secrete incomplete viral particles (capsids). The cells express low to undetectable levels of GFP under basal conditions. Suited to study HIV latency and</p>

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

reactivation.

The clones in this series are: 6.3 (cat# 9846), 8.4 (cat# 9847), 9.2 (cat# 9848), 10.6 (cat# 9849), and 15.4 (cat# 9850).

Please see Table I in the reference publication for differences between these clones in GFP and p24 expression upon stimulation with TNF- α

Recommended Storage:

Keep the reagent in liquid nitrogen.

Contributor:

Dr. Eric Verdin

References:

Jordan, A., Bisgrove, D., & Verdin, E. (2003). HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 22(8), 1868-1877. doi:10.1093/emboj/cdg188 [PUBMED](#)

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Full Length Cells (10.6) from Dr. Eric Verdin." Also include the reference cited above in any publication.

These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: veronica.viray@gladstone.ucsf.edu, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated

December 13, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.